EC3 Economic Burden of Cardiovascular Events in Patients with Chronic Lymphocytic Leukemia Treated with Novel Agents

Novel agent treatments (NATs) have improved survival in chronic lymphocytic leukemia (CLL), but can be associated with increased cardiovascular (CV) events. This analysis examined real-world healthcare costs associated with CV events in CLL patients treated with NATs.

Source: Value in Health - June 1, 2021 Category: International Medicine & Public Health Authors: E. Malangone-Monaco, K. Ryan, E. Marchlewicz, J. Lo, S. Huntington Source Type: research